Characterization of purinergic receptor expression in ARPKD cystic epithelia
- PMID: 30417216
- PMCID: PMC6298916
- DOI: 10.1007/s11302-018-9632-5
Characterization of purinergic receptor expression in ARPKD cystic epithelia
Abstract
Polycystic kidney diseases (PKDs) are a group of inherited nephropathies marked by formation of fluid-filled cysts along the nephron. Growing evidence suggests that in the kidney formation of cysts and alteration of cystic electrolyte transport are associated with purinergic signaling. PCK/CrljCrl-Pkhd1pck/CRL (PCK) rat, an established model of autosomal recessive polycystic kidney disease (ARPKD), was used here to test this hypothesis. Cystic fluid of PCK rats and their cortical tissues exhibited significantly higher levels of ATP compared to Sprague Dawley rat kidney cortical interstitium as assessed by highly sensitive ATP enzymatic biosensors. Confocal calcium imaging of the freshly isolated cystic monolayers revealed a stronger response to ATP in a higher range of concentrations (above 100 μM). The removal of extracellular calcium results in the profound reduction of the ATP evoked transient, which suggests calcium entry into the cyst-lining cells is occurring via the extracellular (ionotropic) P2X channels. Further use of pharmacological agents (α,β-methylene-ATP, 5-BDBD, NF449, isoPPADS, AZ10606120) and immunofluorescent labeling of isolated cystic epithelia allowed us to narrow down potential candidate receptors. In conclusion, our ex vivo study provides direct evidence that the profile of P2 receptors is shifted in ARPKD cystic epithelia in an age-related manner towards prevalence of P2X4 and/or P2X7 receptors, which opens new avenues for the treatment of this disease.
Keywords: ARPKD; ATP; Intracellular calcium flux; Kidney; P2X receptors; P2X4; P2X7; P2rx4; P2rx7; PCK rat; Polycystic kidney disease; Purinergic receptor.
Conflict of interest statement
Conflict of interest
Oleg Palygin declares that he/she has no conflict of interest.
Daria V. Ilatovskaya declares that he/she has no conflict of interest.
Vladislav Levchenko declares that he/she has no conflict of interest.
Christine A. Klemens declares that he/she has no conflict of interest.
Lashodya Dissanayake declares that he/she has no conflict of interest.
Anna Marie Williams declares that he/she has no conflict of interest.
Tengis S. Pavlov declares that he/she has no conflict of interest.
Alexander Staruschenko declares that he/she has no conflict of interest.
Ethical approval
Animal use and welfare adhered to the NIH Guide for the Care and Use of Laboratory Animals following a protocol reviewed and approved by the IACUC at the Medical College of Wisconsin.
Figures








References
-
- Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol. 2006;2(1):40–55. - PubMed
-
- Bergmann C, Senderek J, Kupper F, Schneider F, Dornia C, Windelen E, Eggermann T, Rudnik-Schoneborn S, Kirfel J, Furu L, Onuchic LF, Rossetti S, Harris PC, Somlo S, Guay-Woodford L, Germino GG, Moser M, Buttner R, Zerres K. PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD) Hum Mutat. 2004;23(5):453–463. - PubMed
-
- Kennedy C, Chootip K, Mitchell C, Syed NI, Tengah A. P2X and P2Y nucleotide receptors as targets in cardiovascular disease. Future Med Chem. 2013;5(4):431–449. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous